Nanobiotix S.A. (EPA:NANO)
2.905
-0.035 (-1.19%)
Apr 24, 2025, 5:35 PM CET
Nanobiotix Employees
Nanobiotix had 108 employees as of December 31, 2024. The number of employees increased by 6 or 5.88% compared to the previous year.
Employees
108
Change (1Y)
6
Growth (1Y)
5.88%
Revenue / Employee
€-66,574
Profits / Employee
€630,852
Market Cap
137.71M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 153,498 |
Sanofi | 82,878 |
Sartorius Stedim Biotech | 9,901 |
bioMérieux | 14,754 |
Eurofins Scientific SE | 62,696 |
Ipsen | 5,358 |
Virbac | 5,620 |
emeis Société anonyme | 83,000 |
Nanobiotix News
- 21 days ago - Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Nanobiotix GAAP EPS of -€1.44 - Seeking Alpha
- 22 days ago - NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 24 days ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire
- 4 weeks ago - Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC - GlobeNewsWire
- 5 weeks ago - NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference - GlobeNewsWire
- 5 weeks ago - Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden - Benzinga
- 5 weeks ago - NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 - GlobeNewsWire